Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tier“Nuvation Bio” is a registered trademark of Nuvation Bio Inc. in the U.S. and other countries. Other trademarks or service marks appearing in this report may be trademarks or service marks of other owners.
In the company’s own words · 10-K filed Mar 2, 2026 · SEC EDGAR
Business segments
Q1 2026 · $85.3MThe company’s own SEC segment disclosure.
- License$64.7M76%
- Product$18.5M22%
- Royalty$1.4M2%
- Research And Development Service$700.0K1%
Nuvation Bio Inc. (NUVB) reported revenue of $83M in Q1 2026 (quarter ended March 31, 2026), up 2599% from the same quarter a year earlier. That came with net income of $5.4M (6.5% of revenue). For the full year FY2025, revenue was $63M (+699% year on year) and net income −$205M. Its largest product in 2026-Q1 was License at $65M, 76% of the disclosed total, just ahead of Product at 22%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.